Loading…
GSK plc is projected to rise to $64.02 by 2027, a +21% move from its current price of $52.78. GSK is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $52.07 | $52.80 | $53.55 | +0.04% |
| Jul 13 | $51.78 | $52.82 | $53.88 | +0.08% |
| Jul 14 | $51.57 | $52.84 | $54.14 | +0.12% |
| Jul 15 | $51.40 | $52.86 | $54.37 | +0.16% |
| Jul 16 | $51.25 | $52.88 | $54.57 | +0.20% |
| Jul 17 | $51.12 | $52.90 | $54.75 | +0.23% |
| Jul 18 | $51.00 | $52.92 | $54.92 | +0.27% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $51.00 | $52.92 | $54.92 | +0.27% |
| Week 2 | $50.36 | $53.07 | $55.93 | +0.55% |
| Week 3 | $49.90 | $53.21 | $56.74 | +0.82% |
| Week 4 | $49.55 | $53.36 | $57.47 | +1.10% |
| Week 5 | $49.25 | $53.51 | $58.13 | +1.38% |
| Week 6 | $48.99 | $53.65 | $58.75 | +1.65% |
| Week 7 | $48.77 | $53.80 | $59.34 | +1.93% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments.
The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions.
It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company has a strategic alliance with AN2 Therapeutics, Inc.
for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
GSK plc is a healthcare stock focused on vaccines, specialty medicines, and general medicines with operations in the United Kingdom, the United States, and internationally. Its current price is $50.74 and its market cap stands at $101.68B, with a market rank of 139. The stock shows a constructive long-term price outlook, with a forecast path that implies higher average prices and rising ROIs through 2030 and beyond.
The near term is anchored by a price around the current level, but the longer horizon points to substantial potential in the 2030s and 2040s.
A major floor 10.7% below — a decisive break under it would weaken the trend.
The nearest floor, 7.2% below — buyers have tended to step in here.
Price is pressing into resistance (1.7% away) — a breakout level to watch.
A major ceiling 12.1% above — clearing it would confirm fresh momentum.
Key GSK support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GSK market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $52.84 | Sell | $52.71 | Buy |
| MA 10 | $52.69 | Buy | $52.57 | Buy |
| MA 20 | $52.29 | Buy | $52.27 | Buy |
| MA 50 | $51.40 | Buy | $52.28 | Buy |
| MA 100 | $53.82 | Sell | $52.23 | Buy |
| MA 200 | $50.91 | Buy | $50.28 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.56 | Neutral |
| Stoch RSI (14) | 63.10 | Neutral |
| CCI (20) | 51.99 | Neutral |
| Williams %R (14) | -30.14 | Info |
| MACD (12,26,9) | 0.08 | Buy |
| ROC (12) | 1.36 | Buy |
| Bollinger %B (20,2) | 0.65 | Neutral |
| Stochastic %K (14) | 69.86 | Neutral |
| TRIX (15) | 0.08 | Buy |
| Awesome (5,34) | 1.15 | Buy |
| Ultimate (7,14,28) | 55.73 | Neutral |
| Momentum (10) | 0.89 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 52.75 | Buy |
| ADX (14) | 10.49 | Neutral |
| ATR (14) | 0.66 | Info |
The 30-day technical picture shows bullish sentiment. RSI(14) is 40, with the 50-day simple moving average at $52.51 and the 200-day simple moving average at $50.14. Support is at $49.00 and resistance at $53.04, framing a 30-day range of $46.55 to $55.30. The stock trades near the middle of this range, with annualized volatility of 20%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $47.65 | $52.78 | $67.86 | 0% | Neutral | |
| $52.43 | $64.02 | $81.73 | +21% | Bullish | |
| $62.47 | $77.71 | $101.89 | +47% | Bullish | |
| $69.60 | $87.92 | $117.73 | +67% | Bullish | |
| $69.37 | $88.81 | $121.06 | +68% | Bullish | |
| $74.56 | $96.62 | $133.79 | +83% | Bullish | |
| $80.75 | $105.82 | $148.61 | +100% | Bullish | |
| $83.56 | $110.66 | $157.42 | +110% | Bullish | |
| $100.18 | $133.99 | $192.89 | +154% | Bullish | |
| $110.06 | $148.60 | $216.30 | +182% | Bullish | |
| $149.44 | $210.43 | $320.99 | +299% | Bullish | |
| $252.87 | $381.90 | $624.45 | +624% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $47.65 | $52.78 | $64.16 | +0.00% |
| August 2026 | $47.33 | $55.41 | $66.28 | +4.98% |
| September 2026 | $46.50 | $54.69 | $65.93 | -1.29% |
| October 2026 | $46.36 | $54.76 | $66.44 | +0.12% |
| November 2026 | $47.07 | $55.79 | $68.07 | +1.89% |
| December 2026 | $46.54 | $55.34 | $67.86 | -0.82% |
Click any year to see its month-by-month GSK forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect GSK to range from $47.65 to $67.86 through 2026. The $52.78 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The GSK price prediction for 2027 points to an average of $64.02 (low $52.43, high $81.73) — a potential gain of +21% on today's $52.78. Buyers look set to stay in control over this stretch.
In 2028, GSK is projected to trade between $62.47 and $101.89, averaging $77.71 — a potential gain of +47% from today's $52.78. That is up +21% on the projected 2027 average. Momentum favours further upside here.
GSK plc's 2029 outlook centres on $87.92, within a $69.60 to $117.73 range. That is up +13% on the projected 2028 average. That marks a +67% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, GSK could reach as high as $121.06, with a base case around $88.81 and support toward $69.37 — roughly +68% from $52.78. Momentum favours further upside here.
Expect GSK to range from $74.56 to $133.79 through 2031. The $96.62 average target implies a +83% move from current prices. That is up +9% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The GSK price prediction for 2032 points to an average of $105.82 (low $80.75, high $148.61) — a potential gain of +100% on today's $52.78. Momentum favours further upside here.
In 2033, GSK is projected to trade between $83.56 and $157.42, averaging $110.66 — a potential gain of +110% from today's $52.78. That is up +5% on the projected 2032 average. Buyers look set to stay in control over this stretch.
GSK plc's 2034 outlook centres on $133.99, within a $100.18 to $192.89 range. That is up +21% on the projected 2033 average. That marks a +154% change versus current levels. Momentum favours further upside here.
By 2035, GSK could reach as high as $216.30, with a base case around $148.60 and support toward $110.06 — roughly +182% from $52.78. Buyers look set to stay in control over this stretch.
Expect GSK to range from $149.44 to $320.99 through 2040. The $210.43 average target implies a +299% move from current prices. That is up +42% on the projected 2035 average. Momentum favours further upside here.
The GSK price prediction for 2050 points to an average of $381.90 (low $252.87, high $624.45) — a potential gain of +624% on today's $52.78. Buyers look set to stay in control over this stretch.
Investing $1,000 in GSK today (≈ 18.946571 GSK) could be worth
$7,235.7
+$6,235.7 (+624%) by 2050 · US Dollar
Based on the average projected GSK price of $381.9 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GSKwould be worth at today's price.
$1,000 invested in GSK on Jul 10, 2025 (≈ 25.265284 GSK) would be worth
$1,333.5
+$333.5 (+33.4%) today · 1.33× · US Dollar
Based on a GSK entry price of $39.58 vs. today's $52.78.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $53.66 | $983.6 | -1.6% |
| 1 month ago | $51.17 | $1,031.46 | +3.1% |
| 3 months ago | $58.21 | $906.72 | -9.3% |
| 6 months ago | $50.39 | $1,047.43 | +4.7% |
| 1 year ago | $39.58 | $1,333.5 | +33.4% |
| All time (5.0y) ago | $40.37 | $1,307.41 | +30.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GSK forecast.
Our base-case forecast reaches $110.00 around 2033.
Implied market cap at $110.00: $220.31B
The multi-year forecast paints a steadily strengthening path. The 2026 forecast shows an average price of $50.74 with an average outcome near the current price and a neutral sentiment. From 2027 onward the outlook turns bullish, with an average price of $61.87 in 2027 (ROI 21.9) and continuing to rise to $73.49 in 2028 (ROI 44.8) and $80.81 in 2029 (ROI 59.3).
By 2030 the expected average is $83.30 (ROI 64.2), rising to $89.49 in 2031 (ROI 76.4) and $96.00 in 2032 (ROI 89.2), then $101.56 in 2033 (ROI 100.2) and $121.35 in 2034 (ROI 139.2), followed by $133.63 in 2035 (ROI 163.3). The path extends to $187.78 in 2040 (ROI 270.1) and $329.56 in 2050 (ROI 549.5), all under a bullish sentiment. These are estimates, not guarantees.
Tap a question to reveal the answer.
The forecast shows an average price of $83.30, with a min of $65.03 and a max of $113.65, and a forecast ROI of 64.2, with bullish sentiment.
The outlook turns bullish from 2027 onward with rising averages (61.87 in 2027, 83.30 in 2030, and higher thereafter) and increasing ROI, though 2026 is neutral. These are estimates, not guarantees.
Yes. The 2040 max is $286.56 and the 2050 max is $539.02, indicating the potential to exceed $200 in later years.
The 30-day range is $46.55 to $55.30, RSI(14) is 40, SMA50 is $52.51, SMA200 is $50.14, with support at $49.00 and resistance at $53.04.
Current price is $50.74, market cap is $101.68B, and rank is 139.
GSK plc Community Discussion
0Share your GSK plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.